
The original instrument was prepared by Cheryl Cooper. The following digest, which does not constitute a part of the legislative instrument, was prepared by Thomas L. Tyler.

SB 84 Engrossed

DIGEST
2021 Regular Session

Talbot

Proposed law requires any health coverage plan renewed, delivered, or issued for delivery, in this state to include coverage for genetic or molecular cancer testing including but not limited to tumor mutation testing, next generation sequencing, hereditary germline mutation testing, pharmacogenomic testing, whole exome, genome sequencing and biomarker testing. Provides that coverage may be subject to annual deductibles, coinsurance, copayment provisions consistent with that established under the health coverage plan and that this coverage may be subject to applicable evidence-based medical necessity criteria under the health plan.

Proposed law defines health coverage plan as any hospital, health, or medical expense insurance policy, hospital or medical service contract, employee welfare benefit plan, contract, or other agreement with a health maintenance organization or a preferred provider organization, health and accident insurance policy, or any other insurance contract of this type in the state, including group insurance plans, self-insurance plans, and the office of group benefits programs. Excludes a plan providing coverage for excepted benefits in present law, limited benefit health insurance plans, and short-term policies that have a term of less than 12 months.

Proposed law defines a biomarker and biomarker testing.

Proposed law applies to health coverage plans renewed, delivered, or issued for delivery in their state on or after January 1, 2022.

Effective January 1, 2022.

(Adds R.S. 22:1028.3)

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Insurance to the original bill

1. Removes provisions that the health plan include coverage for the cost of genetic or molecular testing.
2. Adds biomarker testing to provisions regarding genetic or molecular testing for cancer.
3. Provides that coverage may be subject to applicable evidence-based medical necessity criteria.

4. Defines "biomarker" and "biomarker testing".